| Literature DB >> 21856153 |
Christopher McGuigan1, Karolina Madela, Mohamed Aljarah, Arnaud Gilles, Srinivas K Battina, Changalvala V S Ramamurty, C Srinivas Rao, John Vernachio, Jeff Hutchins, Andrea Hall, Alexander Kolykhalov, Geoffrey Henson, Stanley Chamberlain.
Abstract
We have previously reported the power of combining a 5'-phosphoramidate ProTide, phosphate pro-drug, motif with a 6-methoxy purine pro-drug entity to generate highly potent anti-HCV agents, leading to agents in clinical trial. We herein extend this work with the disclosure that a variety of alternative 6-substituents are tolerated. Several compounds exceed the potency of the prior 6-methoxy leads, and in almost every case the ProTide is several orders of magnitude more potent than the parent nucleoside. We also demonstrate that these agents act as pro-drugs of 2'-C-methyl guanosine monophosphate. We have also reported the novel use of hepatocyte cell lysate as an ex vivo model for ProTide metabolism.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21856153 DOI: 10.1016/j.bmcl.2011.06.013
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823